These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 10187120)

  • 1. Tamper-evident packaging requirements for over-the-counter human drug products--FDA. Final rule.
    Fed Regist; 1998 Nov; 63(213):59463-71. PubMed ID: 10187120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Child-resistant packaging for certain over-the-counter drug products. Final rule.
    Consumer Product Safety Commission
    Fed Regist; 2001 Aug; 66(149):40111-6. PubMed ID: 11732555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; amendment of final monograph for OTC antitussive drug products. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Aug; 65(148):46864-8. PubMed ID: 11067707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
    Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug labeling; orally ingested over-the-counter drug products containing calcium, magnesium, and potassium. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Mar; 69(57):13725-35. PubMed ID: 15040351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; final rule for over-the-counter antitussive drug products; technical amendment. Final rule, technical amendment.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Nov; 72(230):67639-40. PubMed ID: 18064767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Over-the-counter human drugs; labeling requirements. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(51):13254-303. PubMed ID: 10557606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical antifungal drug products for over-the-counter human use; amendment of final monograph. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Aug; 65(168):52302-5. PubMed ID: 11067736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediculicide drug products for over-the-counter human use; amendment of final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(250):75414-8. PubMed ID: 14986677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug labeling; sodium labeling for over-the-counter drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Nov; 69(228):69278-80. PubMed ID: 15570675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ophthalmic drug products for over-the-counter human use; proposed amendment of final monograph--FDA. Proposed rule.
    Fed Regist; 1998 Feb; 63(35):8888-90. PubMed ID: 10177740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron-containing supplements and drugs; label warning statements and unit-dose packaging requirements; removal of regulations for unit-dose packaging requirements for dietary supplements and drugs. Final rule; removal of regulatory provisions in response to court order.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Oct; 68(201):59714-5. PubMed ID: 14567392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(90):31123-5. PubMed ID: 12001971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Labeling and effectiveness testing; sunscreen drug products for over-the-counter human use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Jun; 76(117):35620-65. PubMed ID: 21682059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products; technical amendments. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule; technical amendments.
    Fed Regist; 1999 Sep; 64(177):49652-5. PubMed ID: 10915461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Status of certain additional over-the-counter drug category II and III active ingredients--FDA. Final rule.
    Fed Regist; 1998 Apr; 63(77):19799-802. PubMed ID: 10179316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astringent drug products that produce aluminum acetate; skin protectant drug products for over-the-counter human use; technical amendment. Final rule; technical amendment.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Mar; 74(43):9759-65. PubMed ID: 19418638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin protectant drug products for over-the-counter human use; astringent drug products; final monograph; direct final rule. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(114):35290-3. PubMed ID: 12807133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Labeling of diphenhydramine-containing drug products for over-the-counter human use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Dec; 67(235):72555-9. PubMed ID: 12474879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Labeling and effectiveness testing; sunscreen drug products for over-the-counter human use; delay of compliance dates. Final rule; delay of compliance dates; request for comments.
    Food and Drug Administration, HHS
    Fed Regist; 2012 May; 77(92):27591-3. PubMed ID: 22606729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.